Publication

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

Koopman, B., van der Wekken, A. J., Elst, ter, A., Hiltermann, J., Vilacha, J. F., Groves, M., van den Berg, A., Hiddinga, B., Hijmering-Kappelle, L., Stigt, J. A., Timens, W., Groen, H. J. M., Schuuring, E. & Kempen, van, L., 23-Apr-2020, In : JCO Precision Oncology. 4, p. 393-410 18 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Koopman, B., van der Wekken, A. J., Elst, ter, A., Hiltermann, J., Vilacha, J. F., Groves, M., van den Berg, A., Hiddinga, B., Hijmering-Kappelle, L., Stigt, J. A., Timens, W., Groen, H. J. M., Schuuring, E., & Kempen, van, L. (2020). Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. JCO Precision Oncology, 4, 393-410. https://doi.org/10.1200/PO.20.00008

Author

Koopman, Bart ; van der Wekken, A. J. ; Elst, ter, Arja ; Hiltermann, Jeroen ; Vilacha, Juliana F. ; Groves, Matthew ; van den Berg, A. ; Hiddinga, Birgitta ; Hijmering-Kappelle, Lucie ; Stigt, Jos A. ; Timens, Wim ; Groen, Harry J. M. ; Schuuring, Ed ; Kempen, van, Leon. / Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. In: JCO Precision Oncology. 2020 ; Vol. 4. pp. 393-410.

Harvard

Koopman, B, van der Wekken, AJ, Elst, ter, A, Hiltermann, J, Vilacha, JF, Groves, M, van den Berg, A, Hiddinga, B, Hijmering-Kappelle, L, Stigt, JA, Timens, W, Groen, HJM, Schuuring, E & Kempen, van, L 2020, 'Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles', JCO Precision Oncology, vol. 4, pp. 393-410. https://doi.org/10.1200/PO.20.00008

Standard

Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. / Koopman, Bart; van der Wekken, A. J.; Elst, ter, Arja; Hiltermann, Jeroen; Vilacha, Juliana F.; Groves, Matthew; van den Berg, A.; Hiddinga, Birgitta; Hijmering-Kappelle, Lucie; Stigt, Jos A.; Timens, Wim; Groen, Harry J. M. ; Schuuring, Ed; Kempen, van, Leon.

In: JCO Precision Oncology, Vol. 4, 23.04.2020, p. 393-410.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Koopman B, van der Wekken AJ, Elst, ter A, Hiltermann J, Vilacha JF, Groves M et al. Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles. JCO Precision Oncology. 2020 Apr 23;4:393-410. https://doi.org/10.1200/PO.20.00008


BibTeX

@article{ed859e2218f54605b76872491951d0b9,
title = "Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles",
abstract = "PURPOSEMolecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effectiveness of an MTB decision-making methodology for patients with non-small-cell lung cancer (NSCLC) with rare or complex mutational profiles as implemented in the University Medical Center Groningen (UMCG).METHODSThe UMCG-MTB comprises (pulmonary) oncologists, pathologists, clinical scientists in molecular pathology, and structural biologists. Recommendations are based on reported actionability of variants and molecular interpretation of pathways affected by the variant and supported by molecular modeling. A retrospective analysis of 110 NSCLC cases (representing 106 patients) with suggested treatment of complex genomic alterations and corresponding treatment outcomes for targeted therapy was performed.RESULTSThe MTB recommended targeted therapy for 59 of 110 NSCLC cases with complex molecular profiles: 24 within a clinical trial, 15 in accordance with guidelines (on label) and 20 off label. All but 16 recommendations involved patients with an EGFR or ALK mutation. Treatment outcome was analyzed for patients with available follow-up (10 on label and 16 off label). Adherence to the MTB recommendation (21 of 26; 81%) resulted in an objective response rate of 67% (14 of 21), with a median progression-free survival of 6.3 months (interquartile range, 3.2-10.6 months) and an overall survival of 10.4 months (interquartile range, 6.3-14.6 months).CONCLUSIONTargeted therapy recommendations resulting from the UMCG-MTB workflow for complex molecular profiles were highly adhered to and resulted in a positive clinical response in the majority of patients with metastatic NSCLC.",
keywords = "CLINICAL-PRACTICE GUIDELINES, UNIVERSITY-OF-CALIFORNIA, SEQUENCE VARIANTS, DIAGNOSIS, ONCOLOGY",
author = "Bart Koopman and {van der Wekken}, {A. J.} and {Elst, ter}, Arja and Jeroen Hiltermann and Vilacha, {Juliana F.} and Matthew Groves and {van den Berg}, A. and Birgitta Hiddinga and Lucie Hijmering-Kappelle and Stigt, {Jos A.} and Wim Timens and Groen, {Harry J. M.} and Ed Schuuring and {Kempen, van}, Leon",
year = "2020",
month = apr,
day = "23",
doi = "10.1200/PO.20.00008",
language = "English",
volume = "4",
pages = "393--410",
journal = "JCO Precision Oncology",
issn = "2473-4284",
publisher = "AMER SOC CLINICAL ONCOLOGY",

}

RIS

TY - JOUR

T1 - Relevance and Effectiveness of Molecular Tumor Board Recommendations for Patients With Non-Small-Cell Lung Cancer With Rare or Complex Mutational Profiles

AU - Koopman, Bart

AU - van der Wekken, A. J.

AU - Elst, ter, Arja

AU - Hiltermann, Jeroen

AU - Vilacha, Juliana F.

AU - Groves, Matthew

AU - van den Berg, A.

AU - Hiddinga, Birgitta

AU - Hijmering-Kappelle, Lucie

AU - Stigt, Jos A.

AU - Timens, Wim

AU - Groen, Harry J. M.

AU - Schuuring, Ed

AU - Kempen, van, Leon

PY - 2020/4/23

Y1 - 2020/4/23

N2 - PURPOSEMolecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effectiveness of an MTB decision-making methodology for patients with non-small-cell lung cancer (NSCLC) with rare or complex mutational profiles as implemented in the University Medical Center Groningen (UMCG).METHODSThe UMCG-MTB comprises (pulmonary) oncologists, pathologists, clinical scientists in molecular pathology, and structural biologists. Recommendations are based on reported actionability of variants and molecular interpretation of pathways affected by the variant and supported by molecular modeling. A retrospective analysis of 110 NSCLC cases (representing 106 patients) with suggested treatment of complex genomic alterations and corresponding treatment outcomes for targeted therapy was performed.RESULTSThe MTB recommended targeted therapy for 59 of 110 NSCLC cases with complex molecular profiles: 24 within a clinical trial, 15 in accordance with guidelines (on label) and 20 off label. All but 16 recommendations involved patients with an EGFR or ALK mutation. Treatment outcome was analyzed for patients with available follow-up (10 on label and 16 off label). Adherence to the MTB recommendation (21 of 26; 81%) resulted in an objective response rate of 67% (14 of 21), with a median progression-free survival of 6.3 months (interquartile range, 3.2-10.6 months) and an overall survival of 10.4 months (interquartile range, 6.3-14.6 months).CONCLUSIONTargeted therapy recommendations resulting from the UMCG-MTB workflow for complex molecular profiles were highly adhered to and resulted in a positive clinical response in the majority of patients with metastatic NSCLC.

AB - PURPOSEMolecular tumor boards (MTBs) provide physicians with a treatment recommendation for complex tumor-specific genomic alterations. National and international consensus to reach a recommendation is lacking. In this article, we analyze the effectiveness of an MTB decision-making methodology for patients with non-small-cell lung cancer (NSCLC) with rare or complex mutational profiles as implemented in the University Medical Center Groningen (UMCG).METHODSThe UMCG-MTB comprises (pulmonary) oncologists, pathologists, clinical scientists in molecular pathology, and structural biologists. Recommendations are based on reported actionability of variants and molecular interpretation of pathways affected by the variant and supported by molecular modeling. A retrospective analysis of 110 NSCLC cases (representing 106 patients) with suggested treatment of complex genomic alterations and corresponding treatment outcomes for targeted therapy was performed.RESULTSThe MTB recommended targeted therapy for 59 of 110 NSCLC cases with complex molecular profiles: 24 within a clinical trial, 15 in accordance with guidelines (on label) and 20 off label. All but 16 recommendations involved patients with an EGFR or ALK mutation. Treatment outcome was analyzed for patients with available follow-up (10 on label and 16 off label). Adherence to the MTB recommendation (21 of 26; 81%) resulted in an objective response rate of 67% (14 of 21), with a median progression-free survival of 6.3 months (interquartile range, 3.2-10.6 months) and an overall survival of 10.4 months (interquartile range, 6.3-14.6 months).CONCLUSIONTargeted therapy recommendations resulting from the UMCG-MTB workflow for complex molecular profiles were highly adhered to and resulted in a positive clinical response in the majority of patients with metastatic NSCLC.

KW - CLINICAL-PRACTICE GUIDELINES

KW - UNIVERSITY-OF-CALIFORNIA

KW - SEQUENCE VARIANTS

KW - DIAGNOSIS

KW - ONCOLOGY

U2 - 10.1200/PO.20.00008

DO - 10.1200/PO.20.00008

M3 - Article

VL - 4

SP - 393

EP - 410

JO - JCO Precision Oncology

JF - JCO Precision Oncology

SN - 2473-4284

ER -

ID: 120142594